AFP and hepatocellular carcinoma: AI-enhanced liver stiffness measurement (LSM) trends may surpass alpha-fetoprotein (AFP) in predicting HCC risk, particularly in metabolic dysfunction-associated steatotic liver disease (MASLD), where AFP sensitivity is limited [73].